UBS has downgraded Merus NV (MRUS) to Neutral from Buy as of September 29, 2025. The stock is currently priced at $95.73.
This downgrade underscores increased caution regarding the company's outlook. Analysts may be reflecting concerns about competitive pressures, market conditions, or execution risks that could impact performance.
Merus NV is a clinical-stage immuno-oncology company based in the Netherlands, focused on developing bispecific antibody therapeutics. The firm operates in both the Netherlands and the United States, employing 260 full-time staff. Its product pipeline includes zenocutuzumab (Zeno), aimed at treating various solid tumors.
As of November 1, 2025, the analyst consensus for Merus NV includes 3 Strong Buy, 6 Buy, and 14 Hold ratings, totaling 23 analysts. The consensus remains a Buy despite recent downgrades from multiple firms, including Guggenheim and Wells Fargo on the same day as UBS.
Upcoming earnings reports are anticipated on May 5, 2026, with an EPS estimate of -$1.42 and revenue of $11.1 million. The company has faced volatility in earnings performance, with a Q3 2025 EPS of -$1.26, surprising analysts by 10.6%.